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The physiological mechanisms underlying the connection between FGR and susceptibility to adult cardiovascular disease are poorly characterized. One of the causes identified in experimental studies is a decreased cardiomyocyte endowment at birth due to prenatal insults (6, 11, 36) . The fetal heart grows mainly through cell proliferation (hyperplasia), but in the perinatal period, mammalian cardiomyocytes become terminally differentiated, as seen by binucleation and loss of the ability to proliferate. At this point, heart growth occurs mainly through an increase in cardiomyocyte size (hypertrophy). In the growth-restricted fetus, heart size is decreased at term (11, 31, 34, 35) . Since the fetal heart does not grow by increasing cell size, the reduction in heart size in the FGR fetus is due to a reduction in cardiomyocyte number. Because cardiomyocytes mature and exit the cell cycle at birth, the reduction in total number implies a life-long higher mechanical load per individual heart cell. This potentially renders a heart that has smaller margins to compensate for pathologic insults in later life. Although cardiovascular loading in response to hypoxia (increased afterload) could partly compensate for the reduction (or lack of increase) in cardiac output, as shown in fetal mammalian models (see Ref. 18 for a review), such a compensatory response is unlikely in chicken embryos, which respond to hypoxia with hypotension (12, 13, 29) due to predominant vasodilation of the extraembryonic chorioallantoic vasculature (30) .
Cardiomyocyte number at birth is established through fine control of cell proliferation during development (44) . It is, therefore, important to understand whether, how, and when cardiomyocyte proliferation is sensitive to alterations to the prenatal environment. Like mammalian models of developmental hypoxia and nutrient restriction, chicken embryos under chronic hypoxia are also growth restricted (28) . We have previously reported on the growth trajectory of the embryonic chicken heart during chronic hypoxia and have shown that there is a heart-sparing effect up to embryonic day 19 (E19). At this point, relative heart mass is not yet affected by hypoxic incubation but absolute heart size is already reduced (by E18 -E20), likely leaving the hypoxic chick with reduced heart size at hatching (26, 28) . In the rat, maternal hypoxia decreases cardiomyocyte endowment due to premature exit of the cell cycle (1) . During embryonic development, there should be little difference between rat and chick fetal hearts, since both grow mainly through cell proliferation with cardiomyocyte cell cycle exit occurring first after birth/hatching (10, 21, 22 ). Therefore, we tested the hypothesis that the heart of the growth-restricted hypoxic chick embryo has a maintained proliferative activity at E15 but that E19 hearts have decreased cell proliferation, increased apoptosis, and premature cardiomyocyte cell cycle exit and binucleation. We used Ross 308 broiler embryos, a fast-growing chicken breed in which we have earlier shown a higher sensitivity to cardiac stunting due to hypoxic incubation (28) . The work is aimed at answering what causes the reduced heart size in the hypoxic chick embryo and how the structure of the heart is affected.
MATERIALS AND METHODS
Ethics statement. All procedures were approved by Linköpings Djurförsöksetiska Nämnd, the formally appointed district ethical committee under permissions Dnr. 45-03, 48-04, 22-07, and 26-10. Animals. Fertilized eggs from the fast-growing broiler strain Ross 308 were obtained from Lantmännen Swehatch AB (Väderstad, Sweden). Eggs were incubated at 37.8°C and 45% relative humidity (model 25HS, Masallés SA, Sant Cugat del Vallès, Spain) in either normoxic conditions (21% O 2, referred to as N) or hypoxic conditions (14% O2, referred to as H) from day 0 until sampling, as described previously (26) . Eggs were turned 45°to each side of the longitudinal axis of the egg every 90 min. Experiments were performed between embryonic days 7 and 20 (30 -95% of development). Embryos were euthanized by decapitation, and yolk-free embryonic mass was determined to the nearest tenth of a gram (SG-601, Fisher Scientific, Thermo Fisher Scientific). Ventricles were rapidly excised, rinsed in PBS, blotted gently, and weighed to the nearest milligram (Mettler AE260, Mettler Instrumente AG, Zürich, Switzerland) after careful resection of the great blood vessels and the atria. Ventricles were divided into three segments: the apical third was fixed in Bouin's solution for histological preparations, the mid-third was flash frozen and preserved for immunohistochemistry, and the basal third was frozen for later biochemical analysis.
Tissue DNA and protein content. Snap-frozen cardiac tissue was homogenized on ice (Ultra Turrax T8, IKA-Werke, Staufen, Germany) in PBS (for protein quantification) or high salt buffer (0.05 M NaPO 4, 2.0 M NaCl, 2 mM EDTA; for DNA quantification). Protein content was quantified using a commercial kit following the instructions provided by the manufacturer (Pierce BCA kit; Pierce Biotechnology, Rockford, IL). DNA content was quantified by reading fluorescence (excitation: 358 nm, emission: 460 nm) from homogenates labeled with 1 g/ml Hoechst 33258 (Sigma Aldrich, St. Louis, MO) and extrapolating concentrations from a standard curve based on dsDNA from calf thymus (Sigma Aldrich) using a method adapted from Brunk et al. (7) . The experimenter was blind to the origin of the samples at the time of analysis.
Immunohistochemistry, 5-ethynyl-2=-deoxyuridine pulsing, and histology. Ventricular tissues were cut by cryostat (Microm HM 550, Thermo Fisher Scientific) and fixed with 4% paraformaldehyde. For cell density measurements, 30-m sections were stained with 300 nM 4=,6-diamidino-2-phenylindole (DAPI; Invitrogen, Eugene, OR). For mitotic cell density, 25 g of 5-ethynyl-2=-deoxyuridine (EdU; Invitrogen) was injected into the air cell of the egg 8 h prior to sampling. EdU was then detected in 30-m tissue sections using the EdU Click-iT Alexa Fluor 488 kit (Invitrogen, Eugene, OR), as described by the manufacturer. Following mordanting in Bouin's fixative (Sigma Aldrich), paraffin-embedded ventricular 5-m sections were stained with Masson Trichrome staining kit (Sigma Aldrich, St. Louis, MO) to visualize tissue collagen, according to the instructions from the manufacturer. Adult chicken skin was stained in parallel as a positive control. Collagen III, which is increased in rat models of pathological hypertrophy (33) was specifically detected by immunohistochemistry. Cryocut 14-M tissue sections were blocked with 10% rabbit normal serum (Thermo Fisher Scientific), incubated in primary antibody (mouse anti-collagen III IgG, Developmental Studies Hybridoma Bank, Iowa City, IA) at 4°C overnight and in secondary antibody (FITC-conjugated rabbit anti-mouse IgG, Jackson ImmunoResearch Laboratories, West Grove, PA). Apoptotic cells were detected in 14-M tissue sections by TUNEL assay (DeadEnd Fluorometric TUNEL system, Promega, Fitchburg, WI), as described by the manufacturer. The number of animals in each experiment was between seven and nine, the exact numbers are given in the figure legend.
In a parallel set of duplicated slides, EdU-positive cells were identified as cardiomyocytes or fibroblasts using specific cell markers: ␣-actinin for cardiomyocytes and discoidin domain receptor 2 (ddr2) for cardiac fibroblasts (41) . After permeabilization with 0.1% saponin and blocking in 3% goat serum, the slides were incubated at room temperature (1 h) with sarcomeric ␣-actinin primary antibody (Abcam ab9465) followed by overnight incubation at 4°C with ddr2 primary antibody (Santa Cruz sc-8989). Incubation for 1 h at room temperature with a cocktail of secondary goat anti-mouse and goat anti-rabbit Alexa antibodies preceded the EdU Click-iT protocol, which was carried out as described by the manufacturer. Sample size for this experiment was n ϭ 2 per treatment and developmental age.
Cardiomyocyte volume. Cardiomyocytes were isolated enzymatically by retrograde perfusion through the aorta. Coronary perfusion was initiated with Tyrode's solution (in mM: 140 NaCl, 5 KCl, 1 MgCl 2, 10 glucose, 10 HEPES, adjusted with NaOH to pH 7.35) until the heart was blanched and an enzymatic cocktail containing 160 U/ml type II collagenase (Worthington collagenase type 2, 230 U/mg) and 0.78 U/ml protease type XIV (protease from Streptomyces griseus, 3.5 U/mg, Sigma Aldrich) was added to the Tyrode's solution and allowed to circulate for 15 min. The perfusate was then changed to Krebs buffer (KB, in mM: 50 L-glutamic acid, 30 KCl, 20 Taurine, 0.5 EGTA, 10 HEPES, 10 glucose, 30 KH 2PO4, 3 MgSO4, adjusted with KOH to pH 7.37) for 12 min to rinse out the enzymes. Flow rate was maintained at 0.9 ml/min at a pressure of 2-3 kPa, while all of the perfusion solutions were kept at 37°C. Ventricles were then separated from the atria and outflow tract and transferred to KB buffer, while gently shaking the tissue to mechanically dissociate the cells. The crude cell suspension was rested at room temperature for 45 min before residual tissue and visible debris was removed. The cell suspension was fixed in 1% PFA for 10 min at room temperature before cells were transferred to microscope slides, dried, and stained with 3 M 4=,6-diamidino-2-phenylindole (DAPI; Invitrogen). Micrographs were analyzed using image analysis software (NIS-elements AR 3.21.01; Nikon, Shinjuku, Tokyo, Japan) to measure the length and maximal width of the cardiomyocytes. Cell size was calculated as twice the volume of a troncoconical shape with the height of the cone being half of the cell's length. Chicken fetal cardiomyocytes are fusiform in shape, as shown in Fig. 1 , so cell volume can be approximated as a double troncoconical shape with half the cell length as the height of the cone as shown in the figure. The equation below describes the calculation of cell volume based on the parameters specified by Fig. 1 . Wall thickness. Excised hearts were rinsed with PBS through catheters inserted in the pulmonary artery and the aorta. Paraformaldehyde (4%) was subsequently circulated into each ventricle through the catheters using a peristaltic pump set at a low flow (Minipuls 3, Gilson, Middleton, WI). After fixation, methylene blue was added to the perfusate (1% final concentration) to stain the tissue (45 min) to increase the contrast for posterior measurements. The ventricles were later rinsed with PBS to eliminate excess staining and subsequently embedded in cryostat embedding media (Tissue-Tek OCT compound; Sakura, Alphen aan den Rijn, The Netherlands). Embedding medium was injected into the aorta, and the pulmonary artery of the hearts to mimic end-diastolic physiological wall stretch. The injection volumes were 75 l and 125 l for E15 and E19 hearts, respectively and were based on estimated end-diastolic volumes at these stages from literature values of cardiac output and heart rates (19, 42) . Embedded hearts were frozen for 30 min at Ϫ20°C and sectioned at 100 m using a cryostat (Microm HM 550, Thermo Fisher, Thermo Fisher Scientific). Photos of every fifth section (i.e., a spatial resolution of 500 m along the longitudinal axis of the heart) were taken at ϫ20 magnification with a calibrated portable microscope (Mediscope D1, Optilia, Sollentuna, Sweden) placed inside the cryostat chamber. All measurements of left and right ventricular wall thickness and diameter of the heart were obtained in the most caudal picture where the right atrioventricular (AV) valve could be distinguished, using image analysis software (NIS-Elements Advanced Research Laboratory Imaging, NIKON). The right AV valve was chosen as anatomical landmark because of its distinctive appearance in the avian heart. Right ventricular wall thickness was defined as the average of 10 measurements, while left ventricular thickness was defined as the average between the thickness of the free left ventricular wall and the septum (10 single measurements each). The measurements were normalized to the diameter of the heart in that section. Because the sections were typically oval instead of circular, the major and minor diameters of the heart section were measured, and the diameter of the heart was estimated from the expected diameter of a circle with the same area as the oval section.
Bayesian modeling of heart growth and model selection. The aim of the Bayesian analysis was to pinpoint differences between normoxic and hypoxic individuals. We used data-driven models that can incorporate and compare different assumptions about heart development to evaluate growth patterns between E15 and E19 (see APPENDIX for details). Parameters were estimated by combining data of both heart mass and the density of proliferating cells. By investigating whether parameters differed between groups, and if so how, we provided insight into differences in growth pattern. To facilitate reliable conclusions, we implemented three different models for growth, f m(t), each making different assumptions about how growth varies with time. In model m ϭ 1, we assumed a nonvarying growth rate, in model m ϭ 2, growth rate decayed linearly over time, and in model m ϭ 3, growth rate decayed in a nonlinear fashion. The mathematical formulation of each f m(t) function and the corresponding analytical solution for heart size are presented in Table A1 in the APPENDIX.
From the three growth models, we constructed a set of statistical models that took into account all available experimental data, i.e., heart mass (at three stages: E15, E17, and E19) and the density of proliferating cells (at two stages: E15 and E19) in both experimental conditions (normoxia and hypoxia). An explicit mathematical description of the model is provided in the APPENDIX. We were interested in differences in the biologically relevant parameters M0 (heart mass at E15), r0 (growth rate at E15), and r4 (growth rate at E19) and estimated parameters for all combination of these being different or equal between treatments (normoxia vs. hypoxia). A total of 20 candidate models (four for m ϭ 1 and eight each for m ϭ 2 and m ϭ 3) resulted, and we used deviance information criterion (DIC) (39) for model selection, which can be interpreted as the Bayesian equivalent to Akaike's Information Criterion (AIC). Thus, we pursued identification of the most parsimonious model that could explain available data (heart mass and proliferation rate).
Vague priors were implemented in the Bayesian framework, and Markov Chain Monte Carlo techniques were used to obtain posteriors of parameters and DIC for each of the candidate models. This is further described in the APPENDIX.
Data and image analysis. Data are presented as mean (standard deviation) in accordance with the guidelines proposed by CurranEverett and Benos (14) . Comparisons were performed using two-way ANOVA and the Bonferroni post hoc test. The maximal number of multiple comparisons performed was two. Significance is defined as two-tailed P Ͻ 0.05 (*).
DAPI-positive, EdU-positive nuclei, and TUNEL-positive nuclei and collagen were visualized by confocal microscopy (LSM 510 Meta/LSM 700; Carl Zeiss, Oberkochen, Germany). The right ventricular wall was excluded from the analysis, which was focused on interventricular septum and left ventricle.
Images were relabeled by a third party to avoid observer bias, so the experimenter was blind to the origin of the samples. Total cell density based on DAPI staining and the number of EdU-positive cells were counted in confocal z stacks using Imaris software (Bitplane AG, Zurich, Switzerland). Collagen images were quantified using ImageJ (National Institutes of Health, Bethesda, MD) as the percent coverage of the image after applying a common threshold value for all images. Collagen III-and TUNEL density were normalized to the DAPIstained area to account for tissue density and tissue loss in processing.
Cell identification was based on the colocalization of EdU-stained nuclei with the cytoplasmic presence of either ␣-actinin or ddr2. EdU-positive cell nuclei not colocalized with either one of the stains were classified as no-cardiomyocyte no-fibroblast cells.
RESULTS
Hypoxic incubation affects the size of the chick embryo heart. Embryonic growth restriction to chronic hypoxia appeared at E15 and was maintained through E19. From a hypoxic growth restriction of 9% at E15, restriction increased to 34% at E17 and was 22% at E19 ( Fig. 2A) . Effects of hypoxia on absolute heart mass were not significantly different until E19, when H hearts were significantly smaller than N hearts (P Ͻ 0.001) (Fig. 2B) . Relative heart mass (heart mass as % of embryo mass) was larger in hypoxic embryos at E11, E15, E17, and E19 (P ϭ 0.00186, P Ͻ 0.001, P Ͻ 0.001, P Ͻ 0.001, respectively) (Fig. 2C) . The structural composition of the hearts evaluated as total DNA and protein contents was not significantly different with hypoxia at E15 or E19 (Table 1) .
Cell density, cardiomyocyte size, and proliferation rate are not significantly different in hypoxic conditions. Total cell density and proliferating cell density were quantified to determine whether hypoxia affected the number of mitotic EdUpositive cells. Cell density, measured as the total number of DAPI-stained nuclei in confocal image stacks, was not significantly altered in hypoxic hearts at E15 or E19 (Fig. 3A) . Proliferating cell density, determined by the number of cells incorporating EdU in ovo after 8 h, was not significantly affected by hypoxia at E15 or E19, but overall proliferation decreased significantly between days E15 and E19 in both normoxic (P Ͻ 0.001) and hypoxic (P Ͻ 0.01) embryos (Fig.  3B) . Multinucleation status and cell size were measured in isolated cells to assess cell differentiation and check whether cell size could account for the difference in heart size. No binucleated cardiomyocytes were found, and the size of cardiomyocytes from hypoxic embryos was indeed not significantly different from control cardiomyocytes and did not change with developmental stage (Table 1) .
In a subsequent experiment, the identity of proliferating cells was established by colocalization of positive-EdU cell nuclei with specific cell markers (␣-actinin or ddr2). No differences were found between the hypoxic treatment and the normoxic control in either of the two developmental ages, so the results were pooled. Cardiomyocytes amounted to 69 Ϯ 14% (range 51-90%) of the total number of EdU-positive cells, fibroblasts constituted 15 Ϯ 9% (range 7-33%), while other cells amounted to 9 Ϯ 6% (range 0 -18%). A remaining 7 Ϯ 7% (range 0 -16%) of cells showed close colocalization of ␣-actinin or ddr2, and their identity could not be unequivocally established. A representative image showing cell type identification and the nonpooled data are shown in Fig. 4 .
Hypoxia does not trigger apoptosis or remodeling in the embryonic heart. TUNEL assay staining, a common indicator of terminal apoptosis, showed no significant increase in the number of apoptotic cells in the hypoxic groups at E15 or E19 (Fig. 3C ). Wall thickness of the left and right ventricle was measured to evaluate remodeling effects. At E15, neither absolute nor normalized wall thicknesses were significantly different between hypoxic and normoxic hearts (Table 1) . At E19, absolute wall thickness was thinner in both the left and right ventricle, but normalized wall thickness was not significantly changed by hypoxia (Table 1) . To investigate the amount of cardiac fibrosis, collagen type III was visualized by immunohistochemistry. Collagen type III was not significantly altered by hypoxia at E15 or E19, but was significantly increased between E15 and E19 (Fig. 5A) . Total tissue collagen was stained by Masson Trichrome staining of paraffin-embedded ventricular tissue, but collagen content was too small to be reliably quantified (Fig. 5B) .
Bayesian modeling reveals differences in the growth of the heart in hypoxic conditions. Table 2 lists the posteriors estimates of focal parameters along with differences in DIC score. The lowest score (DIC ⌬ ) was found for the linear decrease growth model (m ϭ 2) with treatment differences (N vs. H) in heart mass at E15 (d M0 ϭ 1) and growth rate at E15 (d r0 ϭ 1) but no difference in growth rate at E19 (d r4 ϭ 0). The hypoxic group shows lower posterior estimates of both M 0 and r 0 than the normoxic, indicating that the individuals from the former had smaller hearts at day 15 and grew slower initially. The growth rate difference between treatments was, however, eliminated toward the end of the period.
Beside the model with the lowest score, three other models showed a DIC ⌬ below three and could not be disregarded in the model selection (39) . These models are shown in bold in Table 2 . Effects of hypoxia on embryo and heart mass. Embryo mass (A), heart mass (B), and relative heart mass (C) from normoxic (solid bars) and hypoxic (open bars) chick embryos sampled at embryonic day 7 (E7), E9, E11, E13, E15, E17, and E19. *Significant differences, P Ͻ 0.05, confirmed by experimental data. $Significant difference indicated by Bayesian modeling. n ϭ 10 for E7-E13, n ϭ 14 -17 for E17, n ϭ 98 -101 for E15, n ϭ 118 -120 for E19. . Ventricular wall thickness normalized to the average diameter of the heart. Sample sizes for all groups are between 3 and 6. *Significant difference between the hypoxic treatment and the normoxic controls (P Ͻ 0.05).
The second lowest DIC ⌬ (0.8) is obtained for the m ϭ 3 model that corresponds to the preferred m ϭ 2 model, i.e., differences in terms of M 0 and r 0 , but not r 4 . The posterior estimate of the b 2 parameter was estimated here at 0.009 (Ϫ0.87, 0.87), where values in parenthesis indicate 95% central credibility interval. As this is inclusive of zero, no conclusions can be made about deviation from linearity, and, thus, the biological interpretation of this model is not different from the preferred model. This pattern was found consistently, and Table 2 shows that the DIC ⌬ of the m ϭ 3 models were generally estimated at slightly higher than their m ϭ 2 counterpart.
The third lowest DIC ⌬ (2.0) was obtained for m ϭ 2 with difference between the groups in terms of M 0 , r 0 , and r 4 . Looking at the posterior estimates, the credibility intervals of the two groups are however, very similar for r 4 . Thus, this model also provides no different biological interpretation than the preferred model. Finally, the m ϭ 2 model with no difference in r 0 or r 4 shows a DIC⌬ of 2.5 and cannot be disregarded completely. This model allows for a slightly different biological interpretation, because it suggests that any group difference we see in heart size at day 19 is a result of a difference that was already present at day 15. Fig. 6 further clarifies this concept and plots the difference between this model (gray) and the preferred model (black). Figure 6A shows that the alternative model predicts slightly larger difference between the groups at day 15 and less difference at day 19 than does the preferred model. This is further revealed in the bottom panel, which plots the ratio between the treatments, the relative difference in heart mass between hypoxic treatment, and the normoxic control. The 95% central credibility intervals are exclusive of 1, and we can conclude that irrespective of the model, the groups differ in heart size throughout the period. With the preferred model, the relative difference increases over time, and the difference observed at day 19 is the effect of both the initial difference at day 15 and different growth pattern over the 4-day period. With the alternative model, which has less but not negligible support, the difference at day 19 is just an augmented effect of a difference already present at day 15.
Therefore, the results of the modeling point out a clear difference in absolute heart size at E15, which would be the basis of the differences in heart size at E19. There is also support that this is further explained by lower proliferation rate for the hypoxic group at E15, but this could not be unequivocally determined from the available data.
DISCUSSION
Absolute heart mass in the chick embryo is resilient to the effects of hypoxia until late development, despite the fact that embryonic growth restriction appears at earlier stages. Somatic growth restriction is evident after E13, a time at which the heart maintains an absolute mass comparable to that of normoxic embryos. As a consequence, relative heart mass increases (26, 28) . Experimental data indicate that absolute heart mass is maintained in hypoxic embryos up to E17, while that of hypoxic E19 hearts is reduced, suggesting a hypoxiainduced decrease in growth rate. Closer morphological and histological analyses of E15 and E19 hearts could not reveal significant hypoxia-induced alterations in cell proliferation rate, cell density, apoptosis, or cardiomyocyte size. Furthermore, the absence of binucleated cells indicates that chronic hypoxia does not trigger a premature onset of cardiomyocyte differentiation, as has been observed in rats (1). The finding that proliferative cell density of the heart is not significantly affected by hypoxia does not mean that the proliferative activity, and, thus, the growth rate, of the organ per se is not affected. In the perinatal rat and sheep, cardiomyocyte number is positively correlated to the size of the heart/ventricle (11, 25, 40) , i.e., smaller heart translating to fewer cells. Since cell density and cardiomyocyte size are not affected by hypoxia in our model and, therefore, eliminated as explanations for why the E19 heart is smaller, the only possible explanation left is that the smaller hypoxic hearts contain a reduced "absolute" number of cells. In other words, the unchanged fraction of proliferative cells infers that the smaller hypoxic hearts are growing at a reduced rate due to reduced absolute numbers of mitotic cells. Cardiomyocytes and cardiac fibroblasts together comprise the largest proportion of the cells in the heart, but their relative proportions fluctuate both between species and developmental stages. The neonatal rat and mouse hearts consist of ϳ60% cardiomyocytes and 10%-30% fibroblasts (2). These proportions change by adulthood, to 56% and 30% cardiomyocytes in the mouse and rat hearts, respectively. (2) . Although the cell type composition of the chicken heart has not been evaluated, our study shows that the proportion of proliferating cardiomyocytes and fibroblasts is not affected by hypoxia or developmental age. Given that cell density and collagen deposition are not affected either, there is no evidence that hypoxia alters the cell type distribution in our model. Furthermore, cardiomyocytes still constitute the largest proportion of proliferating cardiac cells, up to 69%, similar to rodent models, which means that changes in cardiac mass due to hypoxia will unequivocally have important effects on the total number of contractile cells.
The heart during prenatal development grows by a wellorchestrated tuning of proliferation and apoptosis (37) . Increased cardiomyocyte apoptosis has, indeed, been found in hypoxic rat pups (1). However, we did not find any hypoxiainduced increase in apoptosis in the hearts of our hypoxic embryos. Combining density of apoptotic cells with total cell density infers that there is one apoptotic cell in ϳ8 000 cells; a density of apoptosis so minute that it is unlikely that cardiomyocyte turnover by apoptosis has any significant effect on heart size at either E15 or E19. Incubation hypoxia did not induce ventricular remodeling in our chicken embryos. Wall thickness, when normalized to the diameter of the heart, was not changed by hypoxia, and there were no signs of pathological thickening or thinning in either the left or the right ventricle. Camm et al. (9) found that maternal hypoxia in rats has no effect on relative ventricular wall thickness of the near-term pups (9). Tintu et al. (45) showed a decrease in absolute left ventricular wall thickness combined with decreased heart mass in E20 White Leghorn layer chicken embryos incubated in 15% O 2 (45) . The heart phenotype of the White Leghorn hypoxic embryos was further characterized as dilated cardiomyopathy with elevated interstitial collagen when analyzed in trichrome sections (45) . Type III collagen is significantly increased in dilated cardiomyopathy, as well as pathological hypertrophy (15, 33) but we did not find hypoxiainduced alterations in type III collagen content or ventricular wall thickness in our broiler chicken model. In fact, we found interstitial collagen content of the E15 and E19 embryos to be so low that the trichrome method was unsuitable for quantification.
Another important finding in this study is that there is no effect of incubation hypoxia on chicken cardiomyocyte size or binucleation. There is also no cell cycle exit or cardiomyocyte hypertrophy in the chicken heart between E15 and E19. This is supported by previous data from Li and coworkers (21) who showed that chicken hearts at the time of hatch contain solely mononucleated cardiomyocytes and that binucleation proceeds slowly. At 42 days post hatching the chicken heart still contains 44% mononucleated cardiomyocytes (21) . In mammals, cardiomyocytes exit the cell cycle around or soon after term. Two of the most commonly used mammalian models to study the effects of FGR are the rat and the sheep. In the rat, binucleation and cell cycle exit of cardiomyocytes occurs between 1 and 2 wk after birth (10, 22) , while in the sheep, cardiomyocytes start maturing at around 0.7 of gestation and ϳ70% are binucleated at term (20) . Studies in these mammalian models show that FGR has effects on cardiomyocyte binucleation and maturation. In sheep cardiomyocyte maturation occurs in response to a rise in triidothyronine (T 3 ) that occurs prenatally (3, 8) . In chicken embryos, a similar rise in T 3 occurs before hatching, but T 3 does not induce maturation of the chicken cardiomyocytes (41, 43) . In the rat model, binucleation and cell cycle exit occurs prematurely in hearts of growth-restricted fetuses (1), while growth-restricted sheep (1) or equal (0) in terms of the focal parameters. Rows with bold entries correspond to models with considerable support (DIC⌬ below three), i.e., models that could not be disregarded in the model selection.
fetuses have hearts with less mature cardiomyocytes (31, 34) and with reduced proliferative activity (31) . This suggests that restriction of fetal growth can affect cardiomyocyte number by altering both myocyte maturity and proliferation rate. These effects are clearly species specific and it is also possible that they differ between causes of restricted fetal growth (e.g., fetal hypoxia vs. protein restriction).
In the rat model, hearts with reduced number of cardiomyocytes can go through catch-up proliferation in the time between birth and terminal cardiomyocyte differentiation (25) . This is possible because rat cardiomyocytes exit the cell cycle 1 to 2 wk after birth (10, 22) . In larger mammals such as in sheep, cardiomyocyte cell cycle arrest is close to complete at term (20) , so the ability of catch-up proliferation after birth seems unlikely. In chicken, cardiomyocytes stay proliferative for at least 42 days posthatching, which makes it possible that the chicken heart has the ability to compensate for the reduced number of cardiomyocytes at hatching through mitosis in postnatal growth. The finding of catch-up proliferation in the rat was done in a model of FGR caused by maternal protein restriction, and the offspring were still growth restricted compared with control rats at 4 wk of age. Li et al. (23) have shown that rat pups subjected to maternal hypoxia go through somatic catch up-growth by 2 mo of age but that the hearts at that time had larger cardiomyocytes than control offspring, suggesting heart catch-up growth through hypertrophy after cardiomyocytes maturation rather than proliferative catch-up growth prior to cell cycle exit (23) . This could mean that limitation of different substrates during fetal development might have different effects on both somatic and cardiac postnatal catch-up growth. We have previously shown that our hypoxic chickens undergo cardiac catch-up growth by 5 wk (26, 27) , and it is of interest to study whether the cardiac catch-up growth occurs through hyperplasia or hypertrophy.
Through Bayesian analysis we could pinpoint the effect of hypoxia on heart growth. The flexibility of the Bayesian framework allowed us to combine multiple data sources (heart mass and proliferation rate), and model selection through DIC promotes identification of models that best describe all available data. This data-driven approach is, therefore, appealing because it allowed us to clarify differences in growth pattern between normoxic and hypoxic individuals, and at the same time illuminate the connection between proliferation rate and heart mass. A clear difference was demonstrated in proliferation rate at E15, and while this difference decreased over time, the difference around E15 was sufficient to explain the difference in heart mass around E19. We were, however, not able to identify a single functional form that describes the change in proliferation rate over the time period; it is decreasing over time from E15 to E19, but we cannot say whether it is linear or nonlinear. This is not essential for our conclusions, but with more data, it would be possible to provide a more detailed description of how proliferation rate changes over time. It is also important to stress that growth models were fitted to the E15-E19 time period, and trends should not be extrapolated outside of that range.
Perspectives and Significance
The Bayesian modeling shows strong support for a difference in growth pattern at around E15, and even subtle differences at this time are sufficient to explain the effects of hypoxia on absolute heart size at E19. The hypoxic hearts are initially spared to the degree that absolute heart size is maintained but, as the embryo grows, the limited substrate delivery in hypoxia decreases the degree of the sparing. In our model, sparing of relative heart mass decreases from 21.1% at E15 to 11.3% at E19. Further, the model supports a reduction in cell proliferation over time, but no difference due to hypoxia at E19. However, at this point the E19 hypoxic heart is 13.2% smaller, and with all other factors studied being unaffected, heart size difference will continue to increase, leaving the hypoxic heart with a reduction in the total number of cardiomyocytes in late development. It is relevant to speculate whether this deviation will be maintained for life and will constitute the basis for a "silent programming" effect or, alternatively, there is a potential for catch-up growth considering that chicken cardiomyocytes are not fully differentiated at hatch (41) and continue proliferating longer than any mammalian species (21) .
Silent programming is evident when the FGR organism is subjected to a "second hit" after birth. This is, for example, shown by the increased susceptibility to ischemia reperfusion injury in adult FGR rats (23, 24, 38) , who show no cardiac impairment in resting conditions. This increased vulnerability has been related to the effect of reduced numbers of cardiomyocytes at birth and the inability of the heart to undergo postnatal catch-up proliferation (32 embryo shows reduced cardiomyocyte endowment, without any signs of pathological remodeling or premature cell cycle exit. Furthermore, the chicken heart consists of cardiomyocytes that are able to proliferate for an extended period after hatching, theoretically enabling catch-up growth by proliferation. This makes the chronic hypoxia exposure of chicken embryos an interesting comparative model to relate a reduction in cardiomyocyte number at birth to adult cardiac dysfunction.
APPENDIX
Growth rate and heart size model. We provide a general model framework to investigate the growth pattern between day 15 and 19. We are interested in the change in heart mass over time and which of the variables measured differ between the low oxygen group (hypoxic) and the normal oxygen control (normoxic). We use days as time units, and for simplicity, we termed day 15 as t ϭ 0 and day 19 as t ϭ 4. We specify a general model for heart growth rate as
where M indicates the mass of the heart and f(t) indicates a function that describes how growth rate of the heart varies with time. We implement three different functions, indicated f m(t) for m ϭ 1, 2, 3, where f1(t) assumes a constant growth rate, f2(t) implements a linear change over time, and f3(t) assumes a nonlinear change. To parameterize in accordance with the focal interest, we express the function in terms of the growth rate at times t ϭ 0 and t ϭ 4, denoted r 0 and r4, and heart mass at t ϭ 0, denoted M0. The functions for m ϭ 1, 2, 3 are explicitly described in Table A1 . For f1(t), r4 ϭ r0. f3(t) requires the additional parameter, b2, which under the present parameterization is interpreted as deviation from linear change in growth rate. For b Ͻ 0, a more rapid change in growth rate occurs in the beginning of the period, and for b Ͼ 0, there is a more rapid change at the end of the period.
An analytical solution for heart size as a function of time and model parameters, M m(t), is available for all chosen fm(t) functions. Table A1 lists the fm(t) functions with the corresponding Mm(t).
Bayesian formulation and model selection. We construct a set of statistical models that takes into account all available experimental data, i.e., heart size and total and proliferating cell densities. Because these data are inherently positive, we focus on log-transformed data and specify the likelihood for log-heart size of individual i in group g (normoxic or hypoxic) at time t, denoted X i,g(t), as
i.e., that Xi,g(t), is normally distributed with mean log [Mm,g(t)], and precision M is a common parameter between groups and times. The extra g in the Mm,g(t) index indicates that this is a group-specific function. Similarly, using Yi,g to denote log-proliferation rate of individual i of group g at time t, this is modeled as
Here, is the ratio between growth rate and proliferation rate, modeled as a common parameter between groups and time. As such, we assume that the relationship between changes in heart mass and proliferation rates is constant irrespective of treatment. Therefore, this parameter is estimated jointly with the parameter of interest for each model. We are interested in group differences in terms of the biologically relevant parameters M 0, r0, and r4 and estimate parameters for all combination of these being different or equal between groups. This provides a total of 20 candidate models (four for m ϭ 1 and eight each for m ϭ 2 and m ϭ 3). We use Deviance Information Criterion (DIC) (39) for model selection, which can be interpreted as a Bayesian equivalent to Akaike's Information Criterion (AIC).
Since we are using a Bayesian framework, priors need to be specified for all parameters. We implement vague priors, thus making inference based primarily on the experimental data. Because we specify the different growth models on the equivalent parameters (M 0, r0, and r4) when possible, we can implement equal priors on corresponding parameters in all models and specify P(M0), P(r0), and P(r4) as proportional to one with the constraint that they are positive. We also specify P() as proportional to one on the real line. For m ϭ 3, we specify P(b 2) as normal (0,0.25), i.e., a distribution with ϳ95% density within the range [Ϫ1, 1]. This allows for a large range of plausible shapes, yet excludes extreme and unrealistic shelf-like behavior in the change of growth rate.
The conjugate prior for precision of the normal distribution is the gamma distribution, here specified by shape ␣ and rate ␤. A vague yet proper prior is obtained for low values of ␣ and ␤, and we specify 
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